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Alfonso Sforzaa, Renata Giudiceb, Bruno Trimarcob and Nicola De LucabObjective Metabolic syndrome (MetS) is associated with
uncontrolled blood pressure (BP), despite use of
aggressive therapy. This study was performed to assess
whether the use of different classes of antihypertensive
drugs might influence this association.
Methods We evaluated risk of uncontrolled BP (BP>—140/
90mmHg under antihypertensive treatment) at the time of
the last available visit, after a mean follow-up of 5 years in
4612 hypertensive patients without prevalent
cardiovascular disease (43% women, 53W11 years) from
the Campania Salute Network.
Results At the time of the first visit, prevalence of MetS was
associated with 43% increased risk of follow-up
uncontrolled BP, independent of significant confounders
and without a significant impact of specific classes of
antihypertensive medications. At the time of the last
available visit, patients with MetS had more often
uncontrolled BP, despite more aggressive treatment. After
adjusting for demographics, risk factors and number of
antihypertensive medications, risk of uncontrolled BP was
reduced with increased prescription of diuretics [DRTs;
odds ratio (OR) 0.73, 95% confidence interval (CI) 0.62–
0.86], renin–angiotensin system blockers [RAS-blockers
(Angiotensin-converting enzyme-inhibitors or angiotensin
receptor blockers); OR 0.77, 95% CI 0.66–0.91] and statinsopyright © Lippincott Williams & Wilkins. Unauth
0263-6352  2011 Wolters Kluwer Health | Lippincott Williams & Wilkins(OR 0.79, 95% 0.68–0.92, all P<0.05), without significant
impact of the other classes of medications.
Conclusion Despite the use of increased number of
medications, hypertensive patients with MetS are at higher
risk of uncontrolled BP. Among classes of antihypertensive
medications, increased prescriptions of DRTs, RAS-
blockers and also statins decrease the probability of poor
BP control. J Hypertens 30:188–193Q 2011 Wolters Kluwer
Health | Lippincott Williams & Wilkins.
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Arterial hypertension is the most prevalent cardiovasular
risk factor in most populations, and the leading cause for
medical consultation and number of drug prescriptions
[1]. It has been estimated that 26 and 28% of incident
cardiovascular disease in men and women, respectively,
are primarily attributable to hypertension [2]. This dis-
appointing impact may be related to the evidence that
blood pressure (BP) in hypertensive patients is still
largely uncontrolled, despite the large number of pre-
scribed medications [3,4]. Furthermore, hypertension is
often part of a constellation of cardiovascular risk factors
including obesity, abnormal glucose homeostasis and
dyslipidemia. These features occur simultaneously more
often than would be expected by chance, supporting the
existence of a discrete disorder called the metabolic
syndrome (MetS) [5–8].
MetS increases cardiovascular risk in the setting of hy-
pertension, even when individual risk factors are taken
into account [9–11], and reduces the probability ofachieving optimal BP control, despite more aggressive
treatment [12–14]. The probability of uncontrolled BP
increases with the number of metabolic risk factors [12],
but whether different medications prescriptions influence
this association has not been clarified yet. Accordingly, this
study was designed to evaluate whether the less effective
BP control in the presence of clusters of risk factors
associated with the phenotype of MetS is at least in part
influenced by specific prescriptions of antihypertensive
medications in a large number of hypertensive patients
referred to a tertiary care center in Southern Italy.
Methods
As previously reported [12,15,16], we have generated an
open electronic registry from a network of 23 community
hospital-based hypertension clinics and 60 general prac-
titioners, referring to the Hypertension Center of the
Federico II University Hospital (Naples, Italy) in the
Campania District (Campania Salute Network, http://
www.campaniasalute.com/). The registry includes overorized reproduction of this article is prohibited.
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demographics and clinical information. After the first
enrollment visit, all participants were followed up at
the Outpatient Clinic of our Hypertension Center.
For the goal of the present study, we selected 7752
hypertensive patients without prevalent cardiovascular
disease (previous myocardial infarction or angina or pro-
cedures of coronary revascularization, stroke or transitory
ischemic attack, congestive heart failure) or diagnosis of
secondary hypertension. From the initial event-free
hypertensive population, 2911 patients were excluded
because of insufficient follow-up period (i.e. last available
visit performed less than 1 year from the initial visit), 27
because of chronic kidney disease more than grade 3 (by
glomerular filtration rate (GFR) estimated by modifi-
cation of diet in renal disease formula [17]) and 202
because missing information on BP or metabolic status.
Thus, the present analysis included 4612 hypertensive
participants, free of prevalent cardiovascular disease. BP
control was assessed in all participants at the time of their
last available visit, after a mean follow-up of
5.0 3.4 years.
The database generation of the Campania Salute Net-
work was approved by the Federico II University Hos-
pital Ethic Committee. Signed informed consent for
using data for scientific purposes was obtained from
all participants.
Measurements and definitions
SBP and DBP were measured by standard aneroid sphyg-
momanometer after 5 min resting in the sitting position,
according to current guidelines [1,18]. We analyzed BP
values obtained at the time of the first and the last
available visits, respectively. Three BP measurements
were obtained during each office visit, at 2-min intervals
and the averages were used for analysis. Hypertension
was defined as SBP of at least 140 mmHg and/or DBP of
at least 90 mmHg or current antihypertensive therapy
[1,19,20]. Under current antihypertensive treatment, BP
less than 140/90 mmHg was considered controlled,
whereas SBP of at least 140 mmHg and/or DBP of at
least 90 mmHg were considered uncontrolled [1,19].
The number and type of antihypertensive medications
prescribed at the time of the first and last available visit
have been analyzed. Medications have been classified as
follows: diuretics (DRTs), b-blockers (including b-block-
ers and a-b-blockers), renin–angiotensin system blockers
(RAS-blockers, including angiotensin-converting enzyme
(ACE)-inhibitors and angiotensin receptor blockers),
calcium channel blockers (CCB) and a-blockers.
Fasting plasma glucose and lipid profile were measured
by standard methods. Diabetes was defined by fasting
glucose of at least 7 mmol/l (126 mg/dl) or by use of
insulin or oral hypoglycemic therapy [20].Copyright © Lippincott Williams & Wilkins. UnautA modified Adult Treatment Panel III (ATP III) defi-
nition of MetS [21] was adopted, changing waist girth
with BMI of at least 30 kg/m2, the cut-point for definition
of obesity, according to National Institute of Health
(NIH) guidelines [22], consistent with a number of
previous studies [9,11,12]. Diagnosis of MetS required
at least two of the following metabolic risk factors, being
the third factor present in all participants (hypertension):
fasting plasma glucose of at least 6.10 mmol/l (110 mg/
dl); plasma triglycerides of at least 1.71 mmol/l (150 mg/
dl); high-density lipoprotein (HDL) cholesterol less than
1.04 mmol/l (<40 mg/dl)for men, or less than 1.30 mmol/l
(<50 mg/dl) for women; and BMI of at least 30 kg/m2 (as a
surrogate of increased waist girth).
Statistical analysis
Data were analyzed using SPSS 12.0 software (SPSS,
Chicago, Illinois, USA) and expressed as mean 1 SD.
Differences between groups with or without follow-up
uncontrolled BP were assessed by analysis of variance. x2-
Statistics were used to determine differences in categ-
orical variables. Logistic regression analysis was used to
identify whether and what classes of medications at the
time of the first visit, were associated with uncontrolled
BP at the end of the follow-up, after hierarchically
adjusting for sex, initial age, smoking status, SBP, heart
rate, BMI, diabetes, plasma creatinine, fasting glucose,
triglycerides, HDL cholesterol and total number of anti-
hypertensive drugs (by a forward stepwise procedure
with P-to-enter< 0.05 and P-to-remove 0.1). The same
model was repeated substituting single metabolic vari-
ables (BMI, fasting glucose, triglycerides and HDL cho-
lesterol) with MetS at the time of the first visit. Logistic
regression was repeated after adjusting for baseline SBP
and anthropometrics, metabolic variables and therapy
detected at the time of the last available visit. Odds of
uncontrolled BP in relation to classes of drugs used at the
time of the last visit were, therefore, evaluated in patients
with MetS separately. Odds ratios (ORs) and 95% con-
fidence interval (CI) for covariates are presented. The
null hypothesis was rejected at two-tailed P value less
than 0.05.
Results
Among 4612 hypertensive patients without prevalent
cardiovascular disease (43% women, mean age
53 11years) at the time of the first visit, 28% were free
of antihypertensive medications. Among treated patients,
51% exhibited initial BP more than 140 and/or 90 mmHg.
At the time of the first visit, obesity was found in 25%,
abnormal fasting glucose in 18% including diabetic
patients (8.6% of the total population), high triglycerides
in 32% and low HDL cholesterol in 34% of the total
population. Smoking habit was found in 1208 participants
(26%). The number of hypertensive patients with initial
MetS was 1461 (32% of study population, 41% women).horized reproduction of this article is prohibited.
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Table 2 Independent initial predictors of follow-up uncontrolled
blood pressure
95% CI for Exp(B)
P value OR Lower Upper
Systolic BP (5 mmHg) 0.0001 1.12 1.10 1.15
BMI (kg/m2) 0.0001 1.03 1.02 1.05
Triglycerides (mmol/l) 0.003 1.12 1.04 1.21
Number of drugs 0.0001 1.20 1.13 1.27
Multivariate analysis; sex, baseline age, heart rate, presence of diabetes, plasma
creatinine, fasting glucose, HDL cholesterol, smoking status and single classes of
antihypertensive medications and statins did not enter the model (all P>0.1). BP,
blood pressure; Exp(B), exponentiation of the B coefficient; HDL, high-density
lipoprotein.Among them, obesity was present in 55%, abnormal
fasting glucose in 42% (diabetes in 20%) and high trigly-
cerides and/or low HDL in 70%.
Proportion of smokers was similar in participants with
MetS compared with those without MetS (27 versus 26%,
P¼ 0.43).
At follow-up, all 4612 participants were treated with
antihypertensive medications, and, among them, 1967
had uncontrolled BP, representing 43% of the total
population. Uncontrolled BP was systolic and diastolic
in 41%, isolated systolic in 45% and isolated diastolic in
14% of cases.Baseline predictors of follow-up uncontrolled blood
pressure
The main initial characteristics of the studied population
in relation to the follow-up BP control are reported in
Table 1. Compared with patients with follow-up con-
trolled BP, those with uncontrolled BP were older, had
higher initial BP, heart rate, BMI, fasting glucose, trigly-
cerides, total cholesterol and serum creatinine levels,
with lower HDL cholesterol and GFR (all P 0.03).
No significant difference was found for smoking status
among participants with or without follow-up uncon-
trolled BP. At the time of the first visit, patients with
follow-up uncontrolled BP had a significant higher preva-
lence of diabetes and MetS compared with those with
follow-up controlled BP (all 0.03<P< 0.0001, Table 1).
Table 2 shows that, at the time of first visit in our
outpatient clinic, higher SBP, BMI, triglycerides and
number of antihypertensive medications independently
increased the probability of uncontrolled BP at the time
of final visit (all P 0.002), without significant effect for
other covariates, including classes of antihypertensive
medications. Initial MetS was associated with 43%
increased probability of uncontrolled BP (OR 1.43,
95% CI 1.25–1.63, P< 0.0001), independent of baseline
SBP, heart rate, presence of diabetes, plasma creatinine,opyright © Lippincott Williams & Wilkins. Unauth
Table 1 Initial clinical characteristic of the hypertensive patients in rel




Heart rate (beats/min) 7411
BMI (kg/m2) 274
Fasting glucose (mmol/l) 5.41.1
Total cholesterol (mmol/l) 5.31.0
HDL cholesterol (mmol/l) 1.30.3
Triglycerides (mmol/l) 1.3 (1.0–1.8)
Creatinine (mmol/l) 8418
GFR (ml/min per 1.73m2) 8218
Smokers (%) 27
Diabetes (%) 8
Metabolic syndrome (%) 28
BP, blood pressure; GFR, glomerular filtration rate; HDL, high-density lipoprotein.smoking status and number or type of initial antihyper-
tensive medications and statins.
Association of uncontrolled blood pressure with classes
of antihypertensive drugs at the time of the last visit
At the time of the last available visit, prevalence of MetS
and diabetes was 33 and 12%, respectively. Prevalence of
uncontrolled BP was higher in participants with MetS
compared with those without MetS (49 versus 40%,
P< 0.0001) and in diabetic compared to nondiabetic
participants (49¼ versus 42%, P¼ 0.002). Mean number
of prescribed antihypertensive medications was signifi-
cantly higher at follow-up compared with the first visit
(2.1 0.9 versus 1.3 0.5, P< 0.0001).
The number of prescribed medications progressively
increased from the group of patients with no metabolic
risk factors to the group of patients with one, two, three or
more clustered risk factors (Fig. 1, P for trend< 0.0001).
In general, single-medication therapy was infrequently
prescribed (31% of total studied population) and more
often in hypertensive without MetS (34 versus 24% of
those with MetS, P< 0.0001).
DRTs, RAS-blockers, CCBs and a-blockers were pre-
scribed more frequently in individuals with MetS than in
those without MetS, without significant differences for
b-blocker prescription (Table 3). Statins were alsoorized reproduction of this article is prohibited.
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Fig. 1
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No RF 1 RF 2 RF 3 or more RF
Mean number of antihypertensive medications prescribed according
to the number of risk factors (RF). N, number of hypertensive patients.
P for trend<0.0001.
Table 4 Independent correlates of uncontrolled blood pressure in
the whole population sample at the time of last available visit
95% CI for Exp(B)
P value OR Lower Upper
Age (year) 0.002 1.01 1.00 1.02
Female sex 0.02 1.18 1.02 1.36
Initial SBP (5 mmHg) 0.0001 1.10 1.09 1.12
Heart rate (beats/min) 0.0001 1.02 1.01 1.03
BMI (kg/m2) 0.0001 1.04 1.03 1.06
Plasma creatinine (5mmol/l) 0.001 1.03 1.01 1.04
Triglycerides (mmol/l) 0.0001 1.17 1.08 1.27
Number of drugs 0.0001 1.27 1.16 1.39
Diuretics (%) 0.0001 0.73 0.62 0.86
RAS-blockers (%) 0.002 0.77 0.66 0.91
Statins (%) 0.003 0.79 0.68 0.92
Multivariate analysis including data detected at the time of the last available visit
(with the exception of baseline SBP); diabetes, fasting glucose, high-density
lipoprotein cholesterol, smoking status, b-blockers, Caþþ-channel blockers,
a-blockers did not enter the model (all P>0.1). BP, blood pressure; CI,
confidence interval; Exp(B), exponentiation of the B coefficient; OR, odds ratio;
RAS-blockers, renin–angiotensin system blockers.
Table 5 Independent correlates of poor blood pressure control at
the time of last available visit in hypertensive patients withprescribed more often in participants with MetS than in
those without MetS (25 versus 22%, respectively,
P¼ 0.02).
We analyzed independent correlates of uncontrolled BP
at the time of the last available visit. Table 4 shows odds
of uncontrolled BP in relation to classes of medications
used at the time of the last available visit, adjusting for
significant confounders. Initial SBP, female sex with
older age, heart rate, BMI, plasma creatinine, triglycer-
ides and higher number of antihypertensive medications
at the time of the last visit were all independently
associated with uncontrolled BP (all 0.02<P< 0.0001).
Among classes of antihypertensive medications, DRTs
and RAS-blockers were less likely to be prescribed when
BP remained uncontrolled (P 0.002), whereas no sig-
nificant influence was observed for b-blocker, CCB or a-
blocker. Prescription of statins reduced by 21% the
probability of uncontrolled BP (P¼ 0.003, Table 4). Less
prescription of DRTs, RAS-blockers and statins were still
related to uncontrolled BP (all P 0.002), also when
analysis was adjusted for the presence of MetS, which
confirmed a 35% higher risk of uncontrolled BP (OR 1.35,
95% CI 1.18–1.54, P< 0.0001).Copyright © Lippincott Williams & Wilkins. Unaut
Table 3 Type of antihypertensive medications prescribed at the






Diuretics (%) 48 56 0.0001
b-Blockers (%) 34 37 ¼0.08
RAS-blockers (%) 76 81 0.0001
Caþþ-channel blockers (%) 32 36 0.006
a-Blockers (%) 9 10 0.05
MetS, metabolic syndrome; RAS-blockers, renin–angiotensin system blockers
(including ACE-inhibitors and angiotensin receptor blockers).Evaluation of antihypertensive therapy in relation to
uncontrolled BP was also carried out in the 1522 hyper-
tensive patients with MetS (Table 5). In this subgroup,
uncontrolled BP was confirmed to be independently
associated with higher baseline SBP and higher number
of medications at the time of the last visit (P< 0.0001).
Prescriptions of DRTs and RAS-blockers were again
associated with 28% reduced probability of uncontrolled
BP in hypertensive patients with MetS, independent of
other confounders (both P< 0.03).
Discussion
Although the effort to reduce and control BP is substan-
tial, and a large number of medications are often pre-
scribed, BP control in populations is still largely
suboptimal [3,4,23]. We and others have previously
reported that prevalence of uncontrolled BP increases
with the number of metabolic risk factors, despite the use
of a greater number of antihypertensive drugs [12–14],
even if BP response to therapy seems not to be affectedhorized reproduction of this article is prohibited.
metabolic syndrome
95% CI for Exp(B)
P value OR Lower Upper
Initial SBP (5 mmHg) 0.0001 1.12 1.10 1.15
Heart rate (beats/min) 0.0001 1.02 1.01 1.03
Number of drugs 0.0001 1.34 1.16 1.56
DRTs (%) 0.02 0.72 0.55 0.94
RAS-blockers (%) 0.03 0.72 0.54 0.97
Multivariate analysis including data detected at the time of the last available visit
(with the exception of initial SBP); sex, age, BMI, diabetes, plasma creatinine,
fasting glucose, triglycerides, smoking status, high-density lipoprotein cholesterol,
b-blockers, Caþþ-channel blockers and a-blockers, statins did not enter into the
model (All P>0.1). BP, blood pressure; CI, confidence interval; DRT, diuretics;
Exp(B), exponentiation of the B coefficient; OR, odds ratio; RAS-blockers; renin-
angiotensin system blockers.
C192 Journal of Hypertension 2012, Vol 30 No 1by presence of MetS [24]. We extended these obser-
vations by analyzing whether different therapeutic strat-
egies could help understanding the apparent resistance to
treatment associated with clusters of metabolic risk fac-
tors. We found that when MetS or single cardiovascular
risk factors were taken into account at the time of initial
visit in our tertiary care center, the classes of antihyper-
tensive drugs used as initial therapy did not influence the
probability of uncontrolled BP at the time of last visit.
Rather, obesity and the associated clustered risk factors
might offset the efficacy of initial therapy. Thus, at the
time of first presentation in our Hypertension Center,
type of antihypertensive therapy had scarce influence on
the outcome of BP controls over time. The discontinuity
and variability of medical care in these patients at the
time of the onset of the study might have influenced
these results.
However, after at least 1 year of strict office controls in our
Hypertension Center, when management of arterial hy-
pertension was obtained following guidelines recommen-
dations [1,18,19], the therapeutic response of these
patients appears influenced also by the choice of specific
classes of antihypertensive drugs. Particularly, DRTs and
RAS-blockers resulted to influence BP control also when
the impact of clustered cardiovascular risk factors and
other classes of antihypertensive medications was taken
into account. DRTs and/or RAS-blockers reduced the
odds of uncontrolled BP at the last visit, and this was
evident either in the whole population sample or in the
subpopulation with MetS, possibly suggesting an
inadequate rate of prescription of these two classes
of medications.
We do not have yet complete available data on variation
of therapy during the follow-up, and we could not evalu-
ate the impact of modification of antihypertensive
therapy with addition and/or substitution of specific
classes of drugs by time varying analysis, and further
studies should be performed to assess this important
issue. Thus, our analysis does not allow drawing
cause–effect conclusions, as the association of uncon-
trolled BP with single classes of medications is influenced
by the cross-sectional nature of the study. The more
frequent prescription of all classes of medications in
patients with uncontrolled BP, especially observed in
those with MetS, reflects the greater, albeit often unsuc-
cessful, effort to control BP in these patients.
The evidence that DRTs were less likely to be pre-
scribed when BP was uncontrolled in hypertensive
patients, including those with MetS, suggests that DRTs
should be probably prescribed more frequently than
found in this analysis to improve control of BP in popu-
lations referred to tertiary care centers. The reasons for
this potential inadequacy of DRT prescription is likely in
the concern, not univocal [25], that DRTs might aggra-
vate metabolic impairment in patients with high risk ofopyright © Lippincott Williams & Wilkins. Unauthdiabetes [26,27], due to the warning issued by some [18],
although not all [1], guidelines. Actually, BP lowering
induced by DRT has shown to significantly reduce
cardiovascular events [28], even in patients with MetS,
in spite of higher incidence of diabetes [29]. We pre-
viously reported in a large population, very similar in
composition to the present one, that uncontrolled BP is a
significant predictor of incident diabetes in the Campania
Salute Network [15], independent of type of antihyper-
tensive therapy, and we also did not find independent
association between DRTs and incident diabetes, once
other metabolic risk factors were taken into account.
However, as diabetes is a major risk factor for microvas-
cular and macrovascular cardiovascular complications,
further studies are needed to determine whether the
potential advantages of more intensive therapy with
DRTs on BP control might balance possible unfavorable
metabolic effects, especially in patients with MetS.
In contrast to debate on DRTs, there is currently large
consensus about use of RAS-blockers in the management
of hypertension, especially in patients with MetS,
wherein they are considered treatment of choice, due
to their benefic effect on insulin sensitivity and glycemic
control [18,19,30]. Activation of the RAS has been associ-
ated with obesity and insulin resistance and has been
proposed to provide a pathophysiologic link among
obesity, diabetes and hypertension [30–32]. The present
results confirm the positive impact of RAS-blockers on
rate of BP control, mainly evident in MetS.
Even interesting and somewhat unexpected is the evi-
dence that prescription of statins reduced the probability
of uncontrolled BP in the whole population sample, but
not in the subpopulation with MetS (in which prescrip-
tion were much more frequent), independent of antihy-
pertensive treatment. These results are consistent with
recent studies showing slight but significant antihyper-
tensive effect of statins, which appear to be independent
of their cholesterol lowering action [33–35]. There are
several mechanisms through which statins may affect BP
[35], inter alia their favorable effects on endothelial
function [36], their interaction with the RAS [37] and
their ability to affect large artery compliance [38].
In conclusion, the effort to control BP in conditions of
exposure to clusters of metabolic disturbances is often
unsuccessful and the addition of subsequent medications
does not necessarily achieve success in BP control. DRTs
and RAS-blockers are possibly underused especially
among hypertensive patients with MetS, wherein they
might emerge as key medications to obtain targeted BP
control. Moreover, statins might also play an important
role in BP control.
Although purely observational, this study suggests that,
in the setting of hypertension, managed in a real-life
context, clustered metabolic risk factors are the most
important predictors of response to therapy and moreorized reproduction of this article is prohibited.
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Clinical trials should be implemented specifically on
the phenotypes of hypertensive patients with MetS,
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